Structure via PubChem · Public domain (PubChem)
clofibrate
Sign in to saveAlso known as Atromid-S®, AY-61123, ICI-28257, alpha-p-Chlorophenoxyisobutyryl ethyl ester, alpha-(p-Chlorophenoxy)isobutyric acid, ethyl ester, Ethyl clofibrate, Ethyl chlorophenoxyisobutyrate, Ethyl 2-(p-chlorophenoxy)isobutyrate
Clofibrate (trade name Atromid-S) is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It belongs to the class of fibrates. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well.
Chemical data
- Formula
- C12H15ClO3
- Molecular weight
- 242.7 g/mol
- IUPAC name
- ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
- SMILES
- CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl
- InChIKey
- KNHUKKLJHYUCFP-UHFFFAOYSA-N
- XLogP
- 3.3
- Polar surface area
- 35.5 Ų
- H-bond donors
- 0
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Research
6,037 papers- Clofibrate.IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans · 1980
- Clofibrate.British medical journal · 1970
- Clofibrate-induced antidiuresis.The Journal of clinical investigation · 1973
- Clofibrate.Lancet (London, England) · 1978
- [Clofibrate--overreaction?].Duodecim; laaketieteellinen aikakauskirja · 1979
via PubMed
~1 min read
Encyclopedic overview
2 sectionsContents
- Complications and controversies
- References
Clofibrate (trade name Atromid-S) is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It belongs to the class of fibrates. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well.
It was patented in 1958 by Imperial Chemical Industries and approved for medical use in 1963. Clofibrate was discontinued in 2002 due to adverse effects.
Excerpted from Wikipedia’s “clofibrate” article, available under the CC BY-SA 4.0 licence.